Jefferies Group restated their buy rating on shares of Shire PLC (NASDAQ:SHPG) in a report issued on Tuesday morning. They currently have a $262.00 price objective on the biopharmaceutical company’s stock.
A number of other research analysts have also issued reports on SHPG. Morgan Stanley reissued an overweight rating on shares of Shire PLC in a report on Friday, June 3rd. Piper Jaffray Cos. reissued a neutral rating and issued a $174.00 target price on shares of Shire PLC in a report on Friday, July 15th. Citigroup Inc. reissued a buy rating on shares of Shire PLC in a report on Wednesday, August 3rd. Leerink Swann reissued an outperform rating and issued a $225.00 target price on shares of Shire PLC in a report on Thursday, May 26th. Finally, Stifel Nicolaus assumed coverage on Shire PLC in a report on Thursday, May 26th. They issued a buy rating and a $230.00 target price on the stock. Four analysts have rated the stock with a hold rating and twenty-three have assigned a buy rating to the stock. The stock currently has an average rating of Buy and a consensus target price of $230.67.
Shire PLC (NASDAQ:SHPG) opened at 203.05 on Tuesday. The stock’s 50 day moving average price is $196.29 and its 200 day moving average price is $184.42. The stock has a market cap of $60.48 billion, a price-to-earnings ratio of 42.20 and a beta of 1.11. Shire PLC has a 12-month low of $147.60 and a 12-month high of $231.32.
Shire PLC (NASDAQ:SHPG) last released its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $3.38 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.03 by $0.35. The business had revenue of $2.43 million for the quarter, compared to analyst estimates of $2.28 billion. Shire PLC had a return on equity of 17.70% and a net margin of 13.19%. The company’s revenue for the quarter was up 55.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.63 earnings per share. Analysts forecast that Shire PLC will post $12.93 EPS for the current fiscal year.
The company also recently disclosed a dividend, which will be paid on Friday, October 7th. Stockholders of record on Friday, September 9th will be issued a $0.139 dividend. The ex-dividend date is Wednesday, September 7th. Shire PLC’s dividend payout ratio (DPR) is 15.63%.
Several institutional investors have recently added to or reduced their stakes in SHPG. Lone Pine Capital LLC purchased a new position in Shire PLC during the second quarter worth approximately $465,566,000. Capital World Investors purchased a new position in Shire PLC during the second quarter worth approximately $285,568,000. Vanguard Group Inc. purchased a new position in Shire PLC during the second quarter worth approximately $278,421,000. FMR LLC increased its position in Shire PLC by 86.7% in the second quarter. FMR LLC now owns 2,663,506 shares of the biopharmaceutical company’s stock worth $490,297,000 after buying an additional 1,237,100 shares during the period. Finally, UBS Group AG increased its position in Shire PLC by 1,825.2% in the first quarter. UBS Group AG now owns 1,227,631 shares of the biopharmaceutical company’s stock worth $211,030,000 after buying an additional 1,163,865 shares during the period. Institutional investors own 24.26% of the company’s stock.
About Shire PLC
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.